中国抗青光眼药物相关眼表疾病诊疗专家共识(2022年)  

Chinese expert consensus on ocular surface diseases related to topical glaucoma medications (2022)

作　　者：中华医学会眼科学分会青光眼学组 王宁利 Glaucoma Group of Ophthalmology Branch of Chinese Medical Association;Wang Ningli(不详;Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing Institute of Ophthalmology,Beijing Key Laboratory of Ophthalmology&Visual Sciences,Beijing 100730,China)

机构地区：[1]不详 [2]首都医科大学附属北京同仁医院北京同仁眼科中心北京市眼科研究所北京市眼科学与视觉科学重点实验室,北京100730

出　　处：《中华眼科杂志》2022年第11期868-871,共4页Chinese Journal of Ophthalmology

摘　　要：青光眼是一种慢性眼病,多数患者需长期甚至终生用药,使用抗青光眼药物引起的眼表疾病严重影响患者的治疗依从性及生活质量,进而降低治疗效果。为了规范抗青光眼药物相关眼表疾病的诊疗工作,改善患者的眼表健康,有效控制青光眼进展,中华医学会眼科学分会青光眼学组以循证为基础,结合我国青光眼患者的基本情况,经过充分讨论,对抗青光眼药物相关眼表疾病的特点、发生机制、危险因素、诊断、治疗及预防和随访提出共识性意见,以期指导临床开展工作。Glaucoma is a chronic progressive sight-threatening eye disease,so most patients need long-term or even lifelong medications.The ocular surface diseases caused by the use of topical glaucoma medications seriously affect the treatment compliance,the quality of life,and the treatment effects.In order to standardize the diagnosis and treatment of topical glaucoma medications-related ocular surface diseases,to improve the ocular surface health of patients and to effectively control the progress of glaucoma,the Glaucoma Group of Ophthalmology Branch of Chinese Medical Association has formulated this consensus after serious consideration and discussion.This evidence-based consensus puts forward suggestions on the characteristics,occurrence mechanism,risk factors,diagnosis,treatment,prevention and follow-up of ocular surface diseases associated with topical glaucoma medications.

关 键 词：青光眼 药物疗法 眼疾病 诊疗准则(主题) 多数赞同 

分 类 号：R775[医药卫生—眼科]